EVOLUS, INC. Capitalized Computer Software, Additions
EVOLUS, INC. (EOLS) reported Capitalized Computer Software, Additions of $594.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-04.
Financial Statements › Notes › Goodwill and Other
us-gaap:CapitalizedComputerSoftwareAdditions · last filed 2026-05-04
- EVOLUS, INC. capitalized computer software, additions for the quarter ending 2026-03-31 was $594.00K, a 68.40% decline year-over-year.
- EVOLUS, INC. capitalized computer software, additions for the quarter ending 2025-12-31 was $1.15M, a 24.46% increase year-over-year.
- EVOLUS, INC. capitalized computer software, additions for the quarter ending 2025-09-30 was $1.11M, a 0.45% decline year-over-year.
- EVOLUS, INC. capitalized computer software, additions for the quarter ending 2025-06-30 was $1.48M, a 76.13% increase year-over-year.
- EVOLUS, INC. capitalized computer software, additions for fiscal 2025 was $5.62M, a 59.95% increase from fiscal 2024.
- EVOLUS, INC. capitalized computer software, additions for fiscal 2024 was $3.51M, a 200.77% increase from fiscal 2023.
- EVOLUS, INC. capitalized computer software, additions for fiscal 2023 was $1.17M, a 11.65% decline from fiscal 2022.
- EVOLUS, INC. capitalized computer software, additions for fiscal 2022 was $1.32M, a 108.85% increase from fiscal 2021.
| Period end | Capitalized Computer Software, Additions 3 month | Capitalized Computer Software, Additions 3 month as first filed | Capitalized Computer Software, Additions 6 month | Capitalized Computer Software, Additions 6 month as first filed | Capitalized Computer Software, Additions 9 month | Capitalized Computer Software, Additions 12 month |
|---|---|---|---|---|---|---|
| 2026-03-31 | $594.00K 10-Q · filed 2026-05-04 | $1.74M derived: sum of 2 quarters · filed 2026-05-04 | $2.85M derived: sum of 3 quarters · filed 2026-05-04 | $4.33M derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2025-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.26M derived: sum of 2 quarters · filed 2026-03-03 | $3.74M derived: sum of 3 quarters · filed 2026-03-03 | $5.62M 10-K · filed 2026-03-03 | ||
| 2025-09-30 | $1.11M 10-Q · filed 2025-11-05 | $2.59M derived: sum of 2 quarters · filed 2025-11-05 | $4.47M 10-Q · filed 2025-11-05 | $5.39M derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2025-06-30 | $1.48M 10-Q · filed 2025-08-05 | $3.36M 10-Q · filed 2025-08-05 | $4.28M derived: sum of 3 quarters · filed 2026-05-04 | $5.40M derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2025-03-31 | $1.88M 10-Q · filed 2026-05-04 | $2.80M derived: sum of 2 quarters · filed 2026-05-04 | $3.92M derived: sum of 3 quarters · filed 2026-05-04 | $4.76M derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2024-12-31 | $920.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.04M derived: sum of 2 quarters · filed 2026-03-03 | $2.88M derived: sum of 3 quarters · filed 2026-03-03 | $3.51M 10-K · filed 2026-03-03 | ||
| 2024-09-30 | $1.12M 10-Q · filed 2025-11-05 | $1.96M derived: sum of 2 quarters · filed 2025-11-05 | $2.59M 10-Q · filed 2025-11-05 | $2.84M derived: sum of 4 quarters · filed 2025-11-05 | ||
| 2024-06-30 | $842.00K 10-Q · filed 2025-08-05 | $1.48M 10-Q · filed 2025-08-05 | $1.73M derived: sum of 3 quarters · filed 2025-08-05 | $2.08M derived: sum of 4 quarters · filed 2025-08-05 | ||
| 2024-03-31 | $635.00K 10-Q · filed 2025-05-07 | $884.00K derived: sum of 2 quarters · filed 2025-05-07 | $1.23M derived: sum of 3 quarters · filed 2025-05-07 | $1.52M derived: sum of 4 quarters · filed 2025-05-07 | ||
| 2023-12-31 | $249.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $598.00K derived: sum of 2 quarters · filed 2025-03-04 | $884.00K derived: sum of 3 quarters · filed 2025-03-04 | $1.17M 10-K · filed 2025-03-04 | ||
| 2023-09-30 | $349.00K 10-Q · filed 2024-11-06 | $635.00K derived: sum of 2 quarters · filed 2024-11-06 | $919.00K 10-Q · filed 2024-11-06 | $1.30M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $286.00K 10-Q · filed 2024-07-31 | $570.00K 10-Q · filed 2024-07-31 | $954.00K derived: sum of 3 quarters · filed 2024-07-31 | $1.49M derived: sum of 4 quarters · filed 2024-07-31 | ||
| 2023-03-31 | $284.00K 10-Q · filed 2024-05-07 | $668.00K derived: sum of 2 quarters · filed 2024-05-07 | $1.20M derived: sum of 3 quarters · filed 2024-05-07 | $1.35M derived: sum of 4 quarters · filed 2024-05-07 | ||
| 2022-12-31 | $384.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $915.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.07M derived: sum of 3 quarters · filed 2023-11-07 | $1.32M 10-K · filed 2023-03-08 | ||
| 2022-09-30 | $531.00K 10-Q · filed 2023-11-07 | $687.00K derived: sum of 2 quarters · filed 2023-11-07 | $938.00K 10-Q · filed 2023-11-07 | $937.00K derived: sum of 4 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $156.00K 10-Q · filed 2023-08-02 | $406.00K 10-Q · filed 2023-08-02 | $406.00K derived: sum of 3 quarters · filed 2023-08-02 | $406.00K derived: sum of 4 quarters · filed 2023-08-02 | ||
| 2022-03-31 | $250.00K 10-Q · filed 2023-05-09 | $250.00K derived: sum of 2 quarters · filed 2023-05-09 | $250.00K derived: sum of 3 quarters · filed 2023-05-09 | $659.00K derived: sum of 4 quarters · filed 2023-05-09 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $0.00 derived: sum of 2 quarters · filed 2023-03-08 | $409.00K derived: sum of 3 quarters · filed 2023-03-08 | $633.00K 10-K · filed 2023-03-08 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | $409.00K derived: sum of 2 quarters · filed 2022-11-08 | $633.00K 10-Q · filed 2022-11-08 | $933.00K derived: sum of 4 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $409.00K 10-Q · filed 2022-08-02 | $633.00K 10-Q · filed 2022-08-02 | $933.00K derived: sum of 3 quarters · filed 2022-08-02 | $1.36M derived: sum of 4 quarters · filed 2022-08-02 | ||
| 2021-03-31 | $224.00K 10-Q · filed 2022-05-10 | $524.00K derived: sum of 2 quarters · filed 2022-05-10 | $956.00K derived: sum of 3 quarters · filed 2022-05-10 | $1.35M derived: sum of 4 quarters · filed 2022-05-10 | ||
| 2020-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $732.00K derived: sum of 2 quarters · filed 2022-03-03 | $1.13M derived: sum of 3 quarters · filed 2022-03-03 | $2.27M 10-K · filed 2022-03-03 | ||
| 2020-09-30 | $432.00K 10-Q · filed 2021-11-02 | $826.00K derived: sum of 2 quarters · filed 2021-11-02 | $1.97M 10-Q · filed 2021-11-02 | $3.08M derived: sum of 4 quarters · filed 2021-11-02 | ||
| 2020-06-30 | $394.00K 10-Q · filed 2021-08-04 | $1.53M 10-Q · filed 2021-08-04 | $1.35M 10-Q · filed 2020-08-10 | $2.65M derived: sum of 3 quarters · filed 2021-08-04 | $3.41M derived: sum of 4 quarters · filed 2021-08-04 | |
| 2020-03-31 | $1.14M 10-Q · filed 2021-05-12 | $2.25M derived: sum of 2 quarters · filed 2021-05-12 | $3.01M derived: sum of 3 quarters · filed 2021-05-12 | $4.55M derived: sum of 4 quarters · filed 2021-05-12 | ||
| 2019-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $1.87M derived: sum of 2 quarters · filed 2021-03-25 | $3.41M derived: sum of 3 quarters · filed 2021-03-25 | $4.42M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $761.00K 10-Q · filed 2020-10-29 | $2.29M derived: sum of 2 quarters · filed 2020-10-29 | $3.30M 10-Q · filed 2020-10-29 | |||
| 2019-06-30 | $1.53M 10-Q · filed 2020-08-10 | $1.30M 10-Q · filed 2019-08-12 | $2.54M 10-Q · filed 2020-08-10 | $2.50M 10-Q · filed 2019-08-12 | ||
| 2019-03-31 | $1.19M 10-Q · filed 2020-05-11 | |||||
| 2018-12-31 | $0.00 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |